The stock will trade on the June 11 interim hemodialysis data readout — a positive result could drive significant upside given the $202M market cap. However, the revenue miss and ongoing cash burn (net cash used $2M in Q1) warrant caution. Monitor for supplemental BLA filing in H2 2026 if data is positive.
Price Chart
Executive Summary
Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both top and bottom lines. The company announced a 25% workforce reduction expected to save $14.3M in 2026, and highlighted upcoming interim Phase 3 hemodialysis data on June 11, 2026 as a key catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 product revenue $0.5M (29 units) vs $0.1M (5 units) in Q1 2025
- EPS -$0.13 vs consensus -$0.12 (miss)
- Revenue $0.5M vs consensus $1.5M (miss)
- Net loss $17.6M vs net income $39.1M in Q1 2025 (driven by non-cash earnout liability change)
- Workforce reduction of ~25% (45 employees) expected to save $14.3M in 2026
- Restructuring charges of ~$0.8M expected in Q2 2026
- Cash and equivalents $48.9M as of March 31, 2026
- Top-line interim results from V012 Phase 3 hemodialysis study expected June 11, 2026
- Purchase commitment of $1.475M from Saudi Arabia for clinical evaluation program
- Appointed new Chief Commercial Officer and Chief Surgical Officer
Financial Impact
Revenue miss of ~$1M vs consensus; net loss of $17.6M; restructuring savings of $14.3M
Risk Factors
- Revenue miss and EPS miss vs consensus
- Ongoing net losses and cash burn
- Dependence on positive Phase 3 hemodialysis data for next catalyst
- Restructuring execution risk and potential further charges
- Dilution risk from equity offerings (raised $23.3M from share sales in Q1 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers